Please login to the form below

Not currently logged in
Email:
Password:

Tecentriq

This page shows the latest Tecentriq news and features for those working in and with pharma, biotech and healthcare.

Roche’s Genetech nabs speedy review for Tecentriq in first-line breast cancer

Roche’s Genetech nabs speedy review for Tecentriq in first-line breast cancer

Roche’ s Genetech nabs speedy review for Tecentriq in first-line breast cancer. ... If all goes well for Roche (and its biotech subsidiary Genetech), then the approval could help boost sales for Tecentriq.

Latest news

  • Ocrevus surge keeps Roche smiling in Q3 Ocrevus surge keeps Roche smiling in Q3

    Tecentriq static. One disappointment for Roche is its new immuno-oncology drug Tecentriq (atezolizumab). ... In the third quarter of this year, sales of Tecentriq were CHF 110m, which is fractionally below its tally in the same period of 2017, and the

  • Keytruda hits survival targets in first-line kidney cancer Keytruda hits survival targets in first-line kidney cancer

    with its IMmotion 151 study comparing PD-L1 inhibitor Tecentriq (atezolizumab) plus Avastin (bevacizumab) to Sutent, which showed positive effects on PFS at this year’s ASCO meeting.

  • A look ahead to key trial readouts at ESMO A look ahead to key trial readouts at ESMO

    Roche’s Tecentriq (atezolizumab) will feature in the Impassion 130 trial as a first-line treatment for triple negative breast cancer (TNBC) as a combination with nab-paclitaxel, with a positive

  • Roche’s Tecentriq misses survival mark in frontline NSCLC Roche’s Tecentriq misses survival mark in frontline NSCLC

    Roche’ s Tecentriq misses survival mark in frontline NSCLC. Keytruda proving hard to beat. ... endpoint. Roche’s PD-L1 inhibitor Tecentriq (pemetrexed) was unable to meet the threshold for a significant improvement in overall survival (OS) when added

  • MSD wins key EU approval for Keytruda, Alimta combo MSD wins key EU approval for Keytruda, Alimta combo

    MSD wins key EU approval for Keytruda, Alimta combo. Decision keeps Keytruda well ahead of rival Tecentriq. ... The news comes after its closest rival, Roche's Tecentriq, saw the FDA last week delay its decision on its use in another first line

More from news
Approximately 36 fully matching, plus 48 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Fishawack Group of Companies

The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics